ARVINAS INC (ARVN) Stock Fundamental Analysis
USA - NASDAQ:ARVN - US04335A1051 - Common Stock
11.53 USD
-1.46 (-11.24%)
ARVN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. The financial health of ARVN is average, but there are quite some concerns on its profitability. ARVN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
ARVN had negative earnings in the past year.
ARVN had a negative operating cash flow in the past year.
In the past 5 years ARVN always reported negative net income.
In the past 5 years ARVN reported 4 times negative operating cash flow.
1.2 Ratios
ARVN's Return On Assets of -7.92% is fine compared to the rest of the industry. ARVN outperforms 69.79% of its industry peers.
ARVN has a better Return On Equity (-11.82%) than 71.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.92% | ||
| ROE | -11.82% | ||
| ROIC | N/A |
ROA(3y)-22.88%
ROA(5y)-19.47%
ROE(3y)-47.01%
ROE(5y)-36.81%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ARVN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ARVN does not have a ROIC to compare to the WACC, probably because it is not profitable.
ARVN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ARVN has been increased compared to 5 years ago.
ARVN has a better debt/assets ratio than last year.
2.2 Solvency
ARVN has an Altman-Z score of 0.31. This is a bad value and indicates that ARVN is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 0.31, ARVN perfoms like the industry average, outperforming 52.60% of the companies in the same industry.
ARVN has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
ARVN has a Debt to Equity ratio of 0.00. This is in the better half of the industry: ARVN outperforms 62.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.31 |
ROIC/WACCN/A
WACC8.82%
2.3 Liquidity
A Current Ratio of 5.63 indicates that ARVN has no problem at all paying its short term obligations.
The Current ratio of ARVN (5.63) is better than 70.31% of its industry peers.
ARVN has a Quick Ratio of 5.63. This indicates that ARVN is financially healthy and has no problem in meeting its short term obligations.
ARVN's Quick ratio of 5.63 is fine compared to the rest of the industry. ARVN outperforms 70.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.63 | ||
| Quick Ratio | 5.63 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 82.66% over the past year.
Looking at the last year, ARVN shows a very strong growth in Revenue. The Revenue has grown by 235.54%.
Measured over the past years, ARVN shows a very strong growth in Revenue. The Revenue has been growing by 43.69% on average per year.
EPS 1Y (TTM)82.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.41%
Revenue 1Y (TTM)235.54%
Revenue growth 3Y78.01%
Revenue growth 5Y43.69%
Sales Q2Q%-59.08%
3.2 Future
ARVN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.24% yearly.
The Revenue is expected to grow by 4.42% on average over the next years.
EPS Next Y55.22%
EPS Next 2Y-6.55%
EPS Next 3Y-4.86%
EPS Next 5Y11.24%
Revenue Next Year-2.7%
Revenue Next 2Y-38.57%
Revenue Next 3Y-27.27%
Revenue Next 5Y4.42%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ARVN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ARVN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ARVN's earnings are expected to decrease with -4.86% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.55%
EPS Next 3Y-4.86%
5. Dividend
5.1 Amount
ARVN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:ARVN (11/19/2025, 2:58:09 PM)
11.53
-1.46 (-11.24%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners93.89%
Inst Owner Change-6.2%
Ins Owners2.15%
Ins Owner Change5.82%
Market Cap846.53M
Revenue(TTM)263.40M
Net Income(TTM)-72.00M
Analysts74.62
Price Target12.69 (10.06%)
Short Float %11.37%
Short Ratio3.28
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)118.06%
Min EPS beat(2)18.03%
Max EPS beat(2)218.09%
EPS beat(4)4
Avg EPS beat(4)76.58%
Min EPS beat(4)18.03%
Max EPS beat(4)218.09%
EPS beat(8)7
Avg EPS beat(8)39.32%
EPS beat(12)8
Avg EPS beat(12)25.06%
EPS beat(16)8
Avg EPS beat(16)4.93%
Revenue beat(2)1
Avg Revenue beat(2)158.66%
Min Revenue beat(2)-27.7%
Max Revenue beat(2)345.02%
Revenue beat(4)2
Avg Revenue beat(4)95.27%
Min Revenue beat(4)-27.7%
Max Revenue beat(4)345.02%
Revenue beat(8)3
Avg Revenue beat(8)23.31%
Revenue beat(12)7
Avg Revenue beat(12)29.15%
Revenue beat(16)9
Avg Revenue beat(16)23.71%
PT rev (1m)3.65%
PT rev (3m)-11.35%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.98%
EPS NY rev (1m)-1.85%
EPS NY rev (3m)18.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-19.05%
Revenue NY rev (1m)-2.43%
Revenue NY rev (3m)-8.39%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.27 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.39 | ||
| P/tB | 1.39 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.81
EYN/A
EPS(NY)-3.14
Fwd EYN/A
FCF(TTM)-5.43
FCFYN/A
OCF(TTM)-5.39
OCFYN/A
SpS5.08
BVpS8.29
TBVpS8.29
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.92% | ||
| ROE | -11.82% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-22.88%
ROA(5y)-19.47%
ROE(3y)-47.01%
ROE(5y)-36.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 70.27% | ||
| Cap/Sales | 0.7% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.63 | ||
| Quick Ratio | 5.63 | ||
| Altman-Z | 0.31 |
F-Score4
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)69.16%
Cap/Depr(5y)101.08%
Cap/Sales(3y)3.18%
Cap/Sales(5y)9.79%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)82.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.41%
EPS Next Y55.22%
EPS Next 2Y-6.55%
EPS Next 3Y-4.86%
EPS Next 5Y11.24%
Revenue 1Y (TTM)235.54%
Revenue growth 3Y78.01%
Revenue growth 5Y43.69%
Sales Q2Q%-59.08%
Revenue Next Year-2.7%
Revenue Next 2Y-38.57%
Revenue Next 3Y-27.27%
Revenue Next 5Y4.42%
EBIT growth 1Y80.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year68.38%
EBIT Next 3Y10.26%
EBIT Next 5YN/A
FCF growth 1Y-23.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.65%
OCF growth 3YN/A
OCF growth 5YN/A
ARVINAS INC / ARVN FAQ
What is the ChartMill fundamental rating of ARVINAS INC (ARVN) stock?
ChartMill assigns a fundamental rating of 3 / 10 to ARVN.
What is the valuation status of ARVINAS INC (ARVN) stock?
ChartMill assigns a valuation rating of 0 / 10 to ARVINAS INC (ARVN). This can be considered as Overvalued.
Can you provide the profitability details for ARVINAS INC?
ARVINAS INC (ARVN) has a profitability rating of 1 / 10.
How financially healthy is ARVINAS INC?
The financial health rating of ARVINAS INC (ARVN) is 4 / 10.